Combined immunodeficiency (CID) is a term used to describe a diverse group of inherited T-cell immunodeficiencies.
1,2 Patients with CID, unlike those with severe combined immunodeficiency (SCID), typically have a substantial body of circulating lymphocytes that are sometimes comparable with those of control subjects but are characteristically dysfunctional. 3 The severity of T-cell dysfunction can vary according to the genotype or even specifically be mutation dependent.
Frequently, CID is caused by hypomorphic mutations in SCID-associated genes, such as IL-2 receptor g (R222C variant), 4 Janus kinase 3 (JAK3) 5 recombination-activating gene (RAG) 1, RAG2, 6 and others. [7] [8] [9] [10] [11] Recently, profound T-cell deficiency was linked to mutations in the caspase activation and recruitment domain family member 11 (CARD11) gene. 12, 13 CARD11 (CARD-containing MAGUK protein 1 [CARMA1] or BIMP3) is a scaffold protein that belongs to a family of membrane-associated guanylate kinases and is required for B-cell receptor and T-cell receptor (TCR) signaling to the nuclear factor kB (NF-kB) transcription factor. This pathway controls an array of genes that participate in lymphocyte differentiation, proliferation, and survival. 14 In resting cells NF-kB is kept inactive in the cytoplasm by IkB inhibitory proteins. On antigen receptor engagement, the IkB kinase complex is activated, resulting in phosphorylation and degradation of IkBs. As a result, NF-kB active transcription factors are liberated, enabling translocation to the cell nucleus and regulation of target genes.
After antigen receptor stimulation, CARD11 undergoes a conformational change from an inactive state to an active scaffold. This change is controlled by the CARD11 inhibitory domain (ID), which is neutralized on serine phosphorylation in part by protein kinase C (PKC) u (T cells) or PKCB (B cells). ID neutralization allows CARD11 to recruit several cofactors, including B-cell lymphoma/leukemia 10 (BCL10), mucosaassociated lymphoid tissue lymphoma translocation gene 1 
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BCL10: B-cell lymphoma/leukemia 10 CARD11: Caspase activation and recruitment domain family member 11 CID: Combined immunodeficiency ID: Inhibitory domain MALT1: Mucosa-associated lymphoid tissue lymphoma translocation gene 1 NF-kB: Nuclear factor kB PE: Phycoerythrin PKC: Protein kinase C PMA: Phorbol 12-myristate 13-acetate SCID: Severe combined immunodeficiency TCR: T-cell receptor WES: Whole-exome sequencing (MALT1), TNF receptor-associated factor 6, TGF-b activated kinase 1, caspase-8, IkB kinase g, casein kinase 1a, and HOIP. [15] [16] [17] The critical role of many components of the signaling cascade in human immunity is highlighted by inherited deleterious mutations that result in lymphocyte dysfunction, causing immunodeficiency. 18, 19 Typically, these patients present in early life with repeated or persistent infections, as well as increased susceptibility to cancer and autoimmunity.
Homozygous null mutations in BCL10 and MALT1 were identified in infants with repeated and severe infections characteristic of CID. 20, 21 In these patients T-cell function and B-cell maturation were consistently aberrant, and NF-kB signaling abrogated. In full agreement with the concept that the CARD11/BCL10/MALT1 signalosome is essential for downstream signaling pathways required for maturation and function of lymphocytes, null mutations in CARD11 lead to a phenotype similar to that of MALT1 and BCL10 deficiencies.
Patients with CARD11 deficiency presented with severe chest infections caused by Pneumocystis jirovecii pneumonia infection. Evaluation of the immune system recorded mostly normal numbers of circulating T and B cells, which were predominately of a naive phenotype and unresponsive to mitogens. Immunoglobulin levels were also reduced. Card11-null mice display similar features. [22] [23] [24] [25] Recently, monoallelic mutations causing gain-of-function CARD11 mutations have also been identified in patients with the lymphoproliferative disorder known as B-cell expansion with NF-kB and T-cell anergy. 26 These patients present shortly after birth with splenomegaly and marked B-cell lymphocytosis of a naive phenotype. They also have repeated microbial infections. Similar to somatic mutations commonly found in large B-cell lymphomas, CARD11 gain-of-function mutations are localized to the CARD, LATCH, and coiled-coil domains. [26] [27] [28] [29] These mutations interfere with autoinhibition by 4 repressive elements in the CARD11 ID and bypass the need for their antigen receptor-induced neutralization. [29] [30] [31] [32] In the unmodulated mouse a homozygous T to A mutation leading to a Leu to Gln (L298Q) amino acid substitution in the coiled-coil domain results in loss of function of the murine CARD11. 23 Unmodulated mice have combined selective defects in both B-and T-cell antigen receptor signaling. 23 Most interestingly, reminiscent of the patients described here, most unmodulated mice gradually have spontaneous progressive atopy consisting of teary eyes and intensely itchy dermatitis in the ear and neck. 23, 33 Histologic inspections of these lesions revealed skin hyperkeratosis and mixed allergic inflammatory infiltrates consisting of mast cells, lymphocytes, and eosinophils. 33 The clinical manifestations observed in patients with CID typically consist of susceptibility to viral, fungal, and microbial infections but frequently include features attributed to immune dysregulation, such as autoimmunity. This is believed to develop because of poorly controlled residual immunity, resulting in a spectrum of disorders, including endocrinopathies, rheumatologic diseases, and hematologic cytopenias.
Severe allergic inflammation was also previously reported in patients with T-cell dysfunction. Severe erythroderma and marked eosinophilia are the hallmarks of Omenn syndrome, which was described in a variety of ''leaky'' defects in SCID-associated genes. [6] [7] [8] [9] 34 Food allergies were also described in patients with immunodysregulation-polyendocrinopathyenteropathy-X-linked syndrome.
Here we describe an autosomal dominant transmission of CID, which consists uniquely of multiorgan severe atopy in addition to susceptibility to infections.
METHODS Patients
Patient data were compiled prospectively and retrospectively from medical records and entered into the Canadian Centre for Primary Immunodeficiency Registry and Tissue Bank, which has been approved by the SickKids Research Ethics Board (protocol no. 1000005598). Consent and assent from each patient and the parents were obtained for genetic testing, including whole-exome sequencing (WES) and whole-genome sequencing analysis, as well as extensive investigations to unravel the functional effect of immune abnormalities. Patients and families have also consented to permit publication of findings.
Exome sequencing and variant calling
DNA from blood of patient 1 was submitted to the Centre for Applied Genomics, Toronto, Ontario, Canada, for exome library preparation and sequencing. DNA was quantified by using the Qubit DNA HS Assay (Life Technologies, Carlsbad, Calif), and 100 ng of input DNA was used for library preparation with the Ion AmpliSeq Exome Kit (Life Technologies), according to the manufacturer's recommendations. The AmpliSeq Exome library was immobilized on Ion PI Ion Sphere particles by using the Ion PI Template OT2 200 Kit v3. Sequencing was performed with the Ion PI Sequencing 200 Kit v3 and Ion PI Chip v2 in the Ion Proton semiconductor sequencing system, according to the manufacturer's recommendations.
Alignment and variant calling were performed with Torrent Suite (v4.0) on the Ion Proton Server by using the Ion Proton AmpliSeq germline low-stringency setting and the hg19 reference genome. The variants were annotated by using an in-house annotation pipeline 35 based on Annovar (November 2014 version) 36 and RefSeq gene models (downloaded from UCSC on August 1, 2015).
Variant prioritization
High-quality variants were prioritized 37, 38 based on (1) allele frequency based on the public databases 1000 Genomes, 39 ExAC, 40 57, 58 and constraint to truncating or missense mutation for heterozygous variants provided by using ExAC. 40 A minimum damaging effect for missense variants was defined as at least 2 of 6 effect predictors and phyloP conservation passing threshold for a damaging effect. 35 Flow cytometry B-and T-cell phenotypes were determined by using flow cytometric analysis with the 4-laser BD analyzer LSR II CFI, BGRV (BD Biosciences, San Jose, Calif). Antibodies used included the following: CD4-BV510, CD3-allophycocyanin, CD127-PerCP-Cy5.5, CD25-BB515, CD194-BV42, CD45RO-phycoerythrin (PE), CD3-PerCP-Cy5.5, CD4-BV510, CD8-BB515, CD183-AF700, CD19-BV711, CD27-BV421, IgD-PE-Cy7, CD24-BB515, CD38-allophycocyanin, CD21-PE-CF594, CD45RO-PE, CD197-BV421, and CD196-PE-Cy7 (BD Biosciences). Anti-IL-4-PE for intracellular staining was from eBioscience (San Diego, Calif), and anti-CD69-PE (eBioscience) and anti-CD25-Alexa Fluor 488 (R&D Systems, Minneapolis, Minn) were used to assess T-cell activation. For activation analyses, peripheral blood lymphocytes were stimulated with 2 mg/mL soluble anti-CD3 (UCHT1) plus 10 mg/mL anti-CD28 (CD28.2) or phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, Mo; 50 ng/mL), as indicated, for 22 to 24 hours and harvested for staining.
Cytokine determinations
Post-Ficoll PBMCs were cultured with PHA or anti-CD3 and anti-CD28 for 48 hours or as indicated, and culture supernatants were collected for analysis by using ELISA. IL-2, IFN-g, IL-4, IL-13, IL-10, IL-5, and IL-17 analysis kits were from R&D Systems. Control data are represented as means 6 SDs. Comparisons among groups were made by using the unpaired t test. An associated probability (P < .05) was considered significant.
Serum concentration of immunoglobulins and specific antibodies
Serum concentrations of immunoglobulins (IgG, IgA, and IgM) were measured by using nephelometry, and IgE concentrations were measured by using RIA with the IgE PRIST kit (Pharmacia Diagnostics, Dorval, Canada). Levels of serum antibodies to tetanus toxoid and pneumococcus (pneumococcal capsular polysaccharide) were measured by means of ELISA, according to the manufacturer's instructions (Binding Site, Birmingham, United Kingdom). Serum antibodies to measles, mumps, and rubella were measured by using ELISA with kits available from Euroimmune (Gross-Groenau, Germany). Serum isohemagglutinin titers were determined by means of 2-fold serial dilution with erythrocytes and are reported as the antiglobulin phase, the dilution at which macroscopic agglutination is observed.
T-and B-cell proliferative responses
Lymphocyte proliferative responses to mitogens, including PHA and the combination of anti-CD3 and anti-CD28 antibodies, and to a panel of recall antigens, including Candida species, tetanus toxoid, herpes zoster, and cytomegalovirus, were determined by using thymidine incorporation. 59 All assays were performed in triplicate and compared with simultaneously stimulated random healthy control subjects.
Assessment of CARD11 R30W signaling activity
HEK293T cells and CARD11-deficient Jurkat T cells (CARD11-KO cells) were cultured as described previously.
15 pcDNA3-based expression vectors for myc-tagged wild-type and R30W CARD11 variants were titrated in HEK293T cells in the presence of 1500 ng of Igk 2 -IFN-LUC and 200 ng of CSK-LacZ reporter and control vectors in transient transfections by using LT-1 (Mirus Bio, Madison, Wis) and 3 mg of total DNA. b-Galactosidase activity in lysates was measured, as previously described, 31 and used to normalize the amounts of lysate for each sample that were resolved on SDS-PAGE gels before analysis by means of Western blotting with anti-myc antibody (sc-40; Santa Cruz Biotechnology, Dallas, Tex). Western blot bands were quantitated with ImageJ software (National Institutes of Health, Bethesda, Md), and linear regression was used to determine the amount of expression vector required to achieve equivalent amounts of wild-type and mutant CARD11 proteins over a 5-fold range of expression (see Fig E1 in this article's Online Repository at www.jacionline.org).
To assess signaling activity, CARD11-KO Jurkat T cells were transiently transfected with 1500 ng of Igk 2 -IFN-LUC, 200 ng of CSK-LacZ, and expression vectors for wild-type and R30W myc-tagged CARD11, as previously described. 60 Each sample was supplemented with empty pcDNA3 to keep the total amount of pcDNA3-based expression vector constant and the total amount of DNA at 3 mg. Forty hours later, cells were treated with 1 mg/mL each of mouse anti-human CD3 (555329; BD PharMingen, San Jose, Calif), mouse anti-human CD28 (555725, BD PharMingen), and rat anti-mouse IgG 1 (553440, BD PharMingen) for 5 hours. Cells were harvested, luciferase and b-galactosidase activities were measured, and fold activation was determined, as previously described. 15 Cofactor interaction studies pcDNA3-based expression vectors for myc-tagged wild-type and R30W CARD11 DID variants were cotransfected into HEK293T cells with expression vectors for FLAG-BCL10, FLAG-MALT1, and untagged BCL10, as indicated, and anti-FLAG immunoprecipitations were performed, as previously described. 16 
T-cell stimulation
Ficoll gradient-purified peripheral blood lymphocytes were stimulated for the indicated times at 378C with either 2 mg/mL anti-CD3 (UCHT1) plus 10 mg/mL anti-CD28 (CD28.2) or PMA (50 ng/mL), as indicated.
RESULTS Patients
A pedigree of the patients described in this study is shown in Fig 1, A. Patient 1. Patient 1 is a 31-year-old woman who has been followed up for CID and severe atopy since the age of 14 years. She was born at term to nonconsanguineous parents of English descent. She had atopic dermatitis from the first few weeks of life. Between 2 and 8 years of age, she experienced multiple episodes of bronchitis, recurrent upper respiratory tract infections, and repeated episodes of sinusitis, which required admission to hospital. During one of these admissions, low serum IgG levels were detected, and she was given replacement intravenous immunoglobulin. She was also given a diagnosis of asthma and environmental allergies. At the age of 9 years, she began experiencing recurrent episodes of diffuse erythematous papular skin lesions on her extremities. A skin biopsy revealed necrotizing granulomatous inflammation. At the age of 15 years, she had repeated exacerbations of oral candidiasis with no preceding treatment with antibiotics or steroids.
At the age of 17 years, she was given a diagnosis of lichen sclerosis of the vulva, which resolved with topical steroid treatment. Subsequently, at age 20 years, she had prolonged and persistent symptoms of abdominal pain and diarrhea and was given a diagnosis of colitis. At age 28 years, she started having scaly skin lesions on her scalp and lower extremities and was given a diagnosis of psoriasis.
A chest computed tomographic scan performed at 18 and 24 years of age confirmed bilateral changes consistent with bronchiectasis.
Patient 2. Patient 2, the daughter of patient 1, was born at term after a normal pregnancy. From 1 week of age, she had eczema, and at 1 month of age, she had asthma. During the first 2 years of life, she experienced multiple episodes of otitis media, 6 episodes of impetigo, and 3 bouts of pneumonia. At age 2 years, she had cellulitis on her hands and face. During the first 2 years of life, she also received a diagnosis of milk allergy, and at the age of 4 years, she received a diagnosis of nut and peanut allergies.
She continues to have severe extensive eczema, as well as repeated episodes of upper and lower respiratory tract infections.
Patient 3. Patient 3 is a 4-year-old boy born at 41 weeks' gestation after a normal pregnancy and spontaneous delivery. He is the son of patient 1 and half-brother of patient 2. His father has another 6-year-old daughter from a previous relationship, who is healthy. He was breast-fed for the first year of life. His first episodes of asthma started at 4 months of age and were exacerbated by repeated respiratory tract infections severe enough to merit hospital admission.
At 6 months of age, on his first exposure to milk product, he had swelling around his lips, eyes, and face and had hives. A similar episode occurred after exposure to egg. At 7 months of age, he was introduced to kiwi for the first time and had lip swelling, hives, and irritability. He also had hives on exposure to shrimp. Since infancy, he has also had eczema, most prominently affecting his hands and face.
Patient 4. Patient 4 is the 37-year-old sister of patient 1. She was assessed because of her striking family history and lifelong struggle with recurrent infections, multiple allergies, and autoimmune manifestations.
During infancy and childhood, she had multiple episodes of upper and lower chest infections that required antibiotic treatment and hospital infections. She was also given a diagnosis of primary infertility, and like her sister, she had lichen sclerosis when she was a teenager.
She too began having severe atopic dermatitis at infancy, which was treated throughout her life with topical steroids, as well as tacrolimus, with only partial response requiring periodical intervention with systemic steroids. Over the past 5 years, the dermatitis was most severe in the periorbital and perianal areas.
Simultaneously, she had difficult-to-control asthma, sometime requiring constant therapy with inhaled steroids and long-acting b-agonists.
The mother of patients 1 and 4 and grandmother of patients 2 and 3 also had severe atopy and asthma since early age, but medical records were unavailable to us. Patients 1 and 4 have 2 male brothers aged 37 and 29 years, who were always healthy with no evidence of atopy. Patients 2 and 3 share a 9-year-old sister who was also always healthy with no signs of atopy or susceptibility to infections.
Identification of CARD11 mutation
Analysis of whole-exome sequencing showed that the subjects did not have any rare (allele frequency, <1%) homozygous or potential compound heterozygous variants with minimum damaging effect and occurrence in genes with immune function or phenotype. The subjects had only 1 variant with 0 frequency in control databases, minimum damaging effect, and occurrence in a gene with established dominant Mendelian inheritance and implicated in human immune disorder, the CARD11 missense variant hg19:chr7:2987341:G>A NM_032415:exon3:c.C88T:p.R30W (CARD11 R30W; Fig 1, A and B) . Sanger sequencing analysis demonstrated that the heterozygous R30W mutation segregated with disease within the family.
CARD11 R30W is a novel variant and has not been previously reported in dbSNP, 61 ClinVar, or HGMD, although it overlaps with a very rare synonymous variant reported in dbSNP (rs145474800). As expected by the dramatic nature of the amino acid change from a positively charged to a bulky aromatic chain, the R30W amino acid change is deemed damaging by SIFT (score 5 0.00), PolyPhen2-HDIV (score 5 1.00), MutationAssessor (score 5 2.76), and CADD (phred score 5 27.30). In addition, R30 is perfectly conserved across 100 vertebrate genome sequences available in UCSC, whereas the genomic position is highly conserved in vertebrates (phyloP score 5 7.47), partially conserved in mammalians (phyloP score 5 1.25), and overlaps a mammalian conserved genome interval (PhastCons score 5 550). R30 maps to the CARD domain 62 in an a-helical secondary structure element (PFAM and SwissProt UCSC annotation track; Fig 1, B) .
In the monomeric CARD structure R30 is adjacent to residues H31 and M32, which, when mutated, disrupt intramolecular interaction with the ID. 29 The R30-M32 region is distinct from the BCL10 interface (R35, K69, K41, and R72; Fig 1, C) .
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Functional effect of the R30W mutation
To assess the effect of the R30W mutation on CARD11 signaling function, we expressed wild-type murine CARD11 and the R30W mutant in CARD11-deficient Jurkat T cells 16 and assayed the cells for TCR-induced activation of NF-kB. 31 First, we titrated expression vectors for wild-type and R30W variants to ensure equivalent expression of each protein in this reconstitution assay (Fig 2, A) . As shown in Fig 2, B, CARD11 -deficient Jurkat T cells, which lack CARD11 expression as a result of CRISPR/Cas9 genomic editing, 16 did not activate the NF-kBresponsive luciferase reporter Igk 2 -IFN-LUC in response to TCR crosslinking with anti-CD3/anti-CD28 antibodies. Although expression of wild-type CARD11 restored TCR-induced NF-kB activation to a level of 72-fold, the expression of an equivalent level of R30W did not rescue signaling at all, indicating that the R30W is a severe loss-of-function mutant (Fig 2, B) .
Because the patients described are heterozygous for the R30W mutation, we assessed the effect of R30W on wild-type CARD11 when coexpressed. First, we coexpressed equivalent levels of wild-type and R30W CARD11 proteins, each at half of the previously assayed level. Surprisingly, the R30W mutant eliminated any signaling activity of coexpressed wild-type CARD11, even though this level of CARD11 expression alone yielded 41-fold TCR-induced activation of NF-kB (Fig 2, B) . The results clearly indicate that the R30W CARD11 mutant has potent dominant negative properties and can severely compromise signaling by a coexpressed wild-type CARD11 allele.
Second, to more closely simulate the conditions in heterozygous cells, we coexpressed wild-type and R30W CARD11 proteins using equivalent amounts of DNA expression vector (Fig 2, C) . Under these conditions, the R30W mutant still displayed potent dominant negative activity, but inhibition of signaling from the wild-type protein was not complete, leading to residual NF-kB activation and reporter stimulation (Fig 2,  C) . At these equivalent DNA expression vector levels, the R30W protein was expressed at approximately 4-fold lower levels than the wild-type protein (Fig 2, D) , which likely explains its incomplete inhibition of the wild-type allele. To verify that the R30W mutant interferes with NF-kB signaling, we have studied FIG 2. CARD11 R30W is a loss-of-function mutant with dominant negative activity. A, Indicated amounts in nanograms of expression vectors for wild-type (WT) or R30W mutant murine myc-CARD11 were expressed in 293T cells with the Igk 2 -IFN-LUC reporter and the CSK-LacZ control, and levels of protein expression were assayed by means of Western blotting (WB) with anti-myc antibodies. B, Jurkat-KO T cells were transfected with Igk 2 -IFN-LUC, CSK-LacZ, and expression vectors for wild-type or R30W CARD11, as indicated. To achieve a relative level of expression referred to as 1.0, 148 and 348 ng of expression vector were used, respectively, for the wild-type and R30W variants. To achieve 50% of that level of expression (referred to as 0.5), 107 and 200 ng of expression vector were used, respectively, for the wild-type and R30W variants. Forty hours after transfection, cells were stimulated for 5 hours with anti-CD3/anti-CD28 treatment and then harvested for luciferase and b-galactosidase assays. C, Jurkat-KO T cells were transfected with Igk 2 -IFN-LUC, CSK-LacZ, and expression vectors for wild-type (WT) or R30W CARD11, as indicated. Forty hours after transfection, cells were stimulated for 5 hours with anti-CD3/anti-CD28 treatment and then harvested for luciferase and b-galactosidase assays. D, Equivalent amounts (107 ng) of expression vectors for wild-type or R30W mutant murine myc-CARD11 were expressed in 293T cells with the Igk 2 -IFN-LUC reporter and the CSK-LacZ control, and levels of protein expression were assayed by means of Western blotting with anti-myc antibodies. E, Peripheral blood lymphocytes of patients 1 and 3 were stimulated with anti-CD3 plus anti-CD28 for the indicated period of time (in minutes). Protein samples were blotted with anti-phospho-p65 NF-kB, demonstrating a markedly diminished phosphorylation of p65 in patients compared with control subjects. F, Western blots show comparable expression of CARD11 in EBV-transformed B-cell lines obtained from patients and control subjects, as indicated.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 p65 NF-kB phosphorylation in the patient's T cells stimulated with anti-CD3 and anti-CD28. Consistent with results in Jurkat T cells, there was a marked reduction when compared with control values (Fig 2, E) . Expression of CARD11 was comparable between the patient and control samples (Fig 2, F) .
Effect of CARD11 R30W on BCL10 and MALT1 association
To assess the effect of R30W on binding to BCL10 and MALT1, we introduced the R30W mutation into the CARD11DID construct, 15 which displays constitutive ability to bind a BCL10/MALT1 complex because of ID absence. CARD11DID simulates the open active conformation of CARD11 that is induced by antigen receptor signaling. 15 On coexpression with FLAG-BCL10, DID R30W showed a modest but clearly reduced ability to coimmunoprecipitate with FLAG-BCL10 compared with the unmutated DID construct (Fig 3) . As previously described, FLAG-MALT1 could only interact with CARD11DID in the presence of untagged BCL10 because MALT1 binds CARD11 through BCL10 (Fig 3) . Again, DID R30W showed a modest but clearly reduced ability to coimmunoprecipitate with FLAG-MALT1 in the presence of coexpressed BCL10 under these conditions (Fig 3) . The results suggest that the R30W mutation can affect CARD11 signaling by preventing optimal association with BCL10 and MALT1.
Effect of CARD11 R30W on immune function
Numbers of circulating CD3
1 T-cell and CD4 1 and CD8 1 subpopulations were found to be normal in all patients. In patients 1 and 2 further analysis of naive and memory (central and effector) T-cell proportions, as well as numbers of regulatory T cells, did not reveal any significant differences from healthy control values (data not shown). However, patient 2 demonstrated an increased proportion of CD3 1 CD4
2
CD8
2 double-negative T cells (12.7% of CD3 1 cells), whereas patient 1 had only a minor increase (3.9%) compared with control values (1% to 1.5%).
Despite apparently normal T-cell populations, in vitro responses to mitogens, such as PHA, were diminished at 19.2% 6 17.3% of control values in all 4 patients (Table I) .
Similarly, optimal stimulation of T cells with anti-CD3 and anti-CD28 was markedly reduced in 3 of 4 patients, implying the presence of a T-cell defect. In vitro responses to a series of antigens, including Candida species, tetanus toxoid, zoster, and cytomegalovirus viruses, were also extremely low in patients 1, 2, and 3 (Fig 4) , suggesting that antigen-specific memory T cells are either lacking or exist at low frequencies in these patients.
This would raise the possibility of an aberrant T-cell expansion repertoire. Indeed, all 4 patients had underrepresentation of between 3 and 6 TCR Vb families while displaying 4 to 7 overrepresented TCR Vb families (Fig 5) (Fig 5) . Abnormal TCR Vb expression is found typically in patients with CID and is suggestive of immune dysregulation.
Further evidence for T-cell dysfunction likely caused by an abnormal NF-kB signaling pathway was revealed on in vitro stimulation of the patient's cells with T-cell mitogens, resulting in marked decreases in levels of IFN-g and IL-2 secretion (Fig 6,  A and B) . In a quest to determine whether T H 2 cells play a major role in this phenotype, we measured cytokine secretion after stimulation of lymphocytes with PHA or anti-CD3 and anti-CD28. Although IL-5 levels were significantly increased after maximum stimulation of T cells (Fig 6, C) , secreted levels of IL-4, IL-10, IL-13, and IL-17 were comparable with control levels (data not shown).
Numbers of CD19/CD20 circulating B cells were also normal in all cases. Further assessment of B-cell development in patients 1 and 2 did not reveal any abnormalities, revealing the presence of naive, transitional, and unswitched and switched memory B cells in normal proportions. Yet serum immunoglobulin levels were low in patient 1 and borderline low in patient 4, whereas the younger subjects (patients 2 and 3) had normal concentrations (Table I) . IgA and IgM levels were normal. Antibody formation in response to vaccination was compromised in patient 1 for both the T cell-dependent and independent antibodies. Antibody levels against tetanus toxoid were normal in the 3 other patients, and antibody levels to mumps were detectable in all patients. Variable antibody levels to measles and rubella were also recorded. The response to challenge with Pneumovax polysaccharide antigens was markedly low in the patients tested (patients 1 and 2) . Similarly, antibody levels to isohemagglutinin were decreased in patient 2 but unfortunately could not be tested in patients 1 and 4 because of their AB 1 blood group.
Assessment of atopy
Serum IgE levels were increased in all 4 patients, and eosinophil numbers were greater than the normal range in 3 of 4 patients (Table I) . Skin testing for various allergens was performed in all 4 patients. A standard panel of allergens, including ragweed, trees, cat, dog, cockroach, feathers, house dust, egg, milk, peanuts, and mixed nuts, was used. Patient 1 was assessed at 17 years of age, and results were positive for ragweed with a wheal of 10 mm, cat with a wheal of 8 mm, and eggs with a wheal of 4 mm; peanuts resulted in a 7-mm wheal, and mixed nuts induced a 3-mm wheal. At the age of 5 years, patient 2 had positive test results to peanut with a wheal of 12 mm, mixed nuts induced a wheal of 22 mm, and milk was positive with a wheal of 6 mm. Patient 3 was studied at 3.5 years, and test results were positive to milk with a wheal of 12 mm, egg with a wheal of 15 mm, mixed nuts with a wheal of 10 mm, and kiwi with a wheal of 6 mm. Patient 4 had positive skin test results to dust mites, feathers, cat, dog, trees, and ragweed. In all patients the histamine positive control had a wheal of 2 mm, and the negative control was 0 mm. Patient 3's ImmunoCAP tests of specific IgE showed 4.65 kU A /L for casein, 8.07 kU A /L for milk, 27.2 kU A /L for egg, and 23.6 kU A /L for egg white. These results correlated well with the clinical history, as well as skin testing, confirming multiple allergies.
Evaluation of the NF-kB pathway function in patients
Previous reports have shown defects in T-cell activation in the absence of CARD11 expression, including specific inhibition of IL-2-high affinity receptor chain (CD25) induction. To assess this possibility, T cells from control subjects and patients were stimulated with a combination of soluble anti-CD3 plus anti-CD28 or the PKC-activating phorbol ester PMA, which activates CARD11 to initiate NF-kB pathway activation, and CD25 induction examined after 24 hours (Fig 7) . A sizeable decrease in CD25 expression was noted with either stimulus in patients' T cells compared with control T cells. The patients' responses suggested that there was a significant blockage in NF-kB activation. In contrast, PMA-induced upregulation of CD69 expression, which has been shown to be unaffected by the loss of CARD11 expression, was essentially normal within the patient group. These findings all strongly support our studies in transfected Jurkat T cells that CARD11 R30W is dominant negative, blocking the activity of the wild-type CARD11 protein.
DISCUSSION
We have described here an extended multigenerational family consisting of 5 members with recurrent viral, fungal, and bacterial infections since infancy, as well as manifesting severe atopy and autoimmune disorders. The index case (patient 1) had 2 affected children conceived from 2 different husbands who were unaffected, one of whom had 1 healthy offspring with another partner, suggesting autosomal dominant inheritance. This combination of features prompted the use of whole-exome studies to identify a causal defect. The sole credible variant identified was a novel mutation in the CARD domain of CARD11. Sanger sequencing verified the variant in patient 1 and validated perfect segregation in the other family members. These findings could not explain the phenotype based on previous immunodeficiencies described with mutations in CARD11. were assessed by means of flow cytometry. All 4 patients had underrepresentation of 3 to 6 TCR Vb families, and 4 to 7 overrepresented TCR Vb families. The mean 6 SD value was determined by assessing a large number of control subjects (>75 healthy subjects, mostly children).
Heterozygous mutations in CARD11 were previously reported in patients with B-cell expansion with NF-kB and T-cell anergy, who, unlike our patients, typically present in infancy with B-cell lymphoproliferation. In contrast, monoallelic loss-of-function mutations found in parents of patients with autosomal recessive CARD11 deficiency were asymptomatic. 13 Because the clinical manifestations of the patients were consistent with CID and atopy, we hypothesized that R30W CARD11 was a heterozygous mutant with a dominant negative effect. This was supported by the observation that a homozygous loss-of-function mutation in CARD11 leads to severe atopy in the immunodeficient unmodulated mouse. 23, 33 Indeed, transfection of the CARD11 R30W mutant into CARD11-deficient Jurkat T cells demonstrated markedly reduced NF-kB induction compared with the wild-type. Moreover, cotransfection of R30W CARD11 along with wild-type CARD11 resulted in dramatic suppression of wild-type-mediated NF-kB activation, indicating a strong dominant negative effect. This observation was further confirmed in primary lymphocytes of the patients.
It appears from our cofactor interaction studies that the R30W mutation modestly affects the ability of CARD11 to bind to BCL10 and MALT1 through BCL10. The effect on BCL10 binding could explain the signaling defect of the R30W mutant if a certain threshold of cofactor interaction not met by the R30W variant is required for signaling to NF-kB. Alternately, it is possible that a distinct step in CARD11 signaling is also affected by the R30W mutation and that R30 participates in an interaction with an undetermined positive signaling cofactor or promotes a conformation of CARD11 required for signaling. Because CARD11 functions as an oligomer of undetermined stoichiometry, the R30W mutation could interfere with CARD11-CARD11 interactions within the same molecule or between distinct subunits in an oligomer.
The ablative effect of R30W on NF-kB signaling was consistent with the markedly reduced TCR-triggered secretion of IL-2 and IFN-g, as well as proliferative responses to mitogens and antigens. Together, these findings can explain manifestations of repeated and severe infections. Despite these functional T-cell defects, the number of circulating T cells and the proportion of naive and memory, as well as regulatory, T cells remained largely intact. However, analysis of TCR Vb families revealed a significant skewing of the T-cell repertoire. Of note is the overrepresentation of several TCR Vb families, suggesting clonal expansion, which is frequently seen in patients with CID 64, 65 and is reminiscent of observations in patients with autoimmune disorders. 66 These results are consistent with the multiple autoimmune disorders observed in R30W 2/1 patients. The number of circulating B cells in our cohort was consistently normal, but IgG levels and the ability to produce specific antibodies in response to vaccinations were variable. Patients 1 and 4 had low serum IgG levels, but only patient 1 had a universal inability to produce specific antibodies.
The phenotypic difference between autosomal recessive CARD11 deficiency and the heterozygous R30W carriers is striking, suggesting that signaling downstream of CARD11 in our patients is not as universally and completely ablated, despite the strong dominant negative effect of the mutant CARD11 in the Jurkat T-cell assay. Induction of CD25 expression in primary T-cell activation assays showed a significant reduction in R30W T cells compared with normal values (typically <50%); however, although blunted, responses were not absent. PMA-induced responses were found to be enhanced by costimulation with anti-CD28 in all patients (data not shown), demonstrating that maximal stimulation is capable of inducing some significant activation. The residual signaling activity observed in the patients' cells was mimicked in our NF-kB reporter assay in Jurkat T cells when we used equivalent levels of DNA expression vectors for wild-type and R30W CARD11 (Fig 2, C) . Under these conditions, wild-type CARD11 is expressed at approximately 4-fold higher levels than the R30W mutant, likely leading to a fraction of wild-type CARD11 proteins that is resistant to the dominant negative effect of R30W.
The precise mechanism underlying the severe atopy afflicting patients with R30W defects remains largely unclear and requires further extensive investigation. We explored the possibility that an increase in levels of T H 2-secreted cytokines occurred in these patients. Both T H 2 and some T H 1 and CD8 1 cells were implicated in orchestrating allergic inflammation through release of the cytokines IL-4, IL-5, IL-9, and IL-13. Although IL-5 secretion from circulating T cells was increased, secretion of IL-4 and IL-13 was indistinguishable from control values. Increased secretion of IL-5 is consistent with the increase in eosinophil numbers in these patients, but the concomitant increase in total IgE and specific antibodies could not be explained by these results. It is still possible that the increase in IgE levels can be triggered by increased IL-4 and IL-13 levels stemming from tissue-infiltrating T H 2 cells. Alternately, it is possible that the expanded CD8
1 T cells found in the patients' infiltrated tissues also secrete T H 2 cytokines.
In conclusion, for the first time, we have described here an autosomal dominant transmission of CARD11 deficiency caused by a dominant negative mutation. The clinical spectrum in this disorder is unique, encompassing recurrent infections, autoimmunity, and severe atopy. The novel R30W mutations described abrogate the NF-kB pathway and lead to decreased IL-2 and IFN-g secretion and lymphocyte proliferation. The signaling defect results in a unique form of CID with prominent features of autoimmunity and atopy.
Clinical implications: A single dominant negative gene defect in CARD11 can cause CID, autoimmunity, and multiorgan atopy. 
